A Combined Transcriptomic and Genomic Analysis Identifies a Gene Signature Associated With the Response to Anti-TNF Therapy in Rheumatoid Arthritis

• Published in: Frontiers in immunology 2019, Vol.10, p.1459-1459
• Main Authors: Aterido, Adrià, Cañete, Juan D, Tornero, Jesús, Blanco, Francisco, Fernández-Gutierrez, Benjamín, Pérez, Carolina, Alperi-López, Mercedes, Olivè, Alex, Corominas, Héctor, Martínez-Taboada, Víctor, González, Isidoro, Fernández-Nebro, Antonio, Erra, Alba, López-Lasanta, María, López Corbeto, Mireia, Palau, Núria, Marsal, Sara, Julià, Antonio
• Format: Article
• Language: English
• Subjects: Anti-TNF therapy; Genomics; Immunology; Multi-omics association analysis; Rheumatoid arthritis; Transcriptomics
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2019.01459

Rheumatoid arthritis (RA) is the most frequent autoimmune disease involving the joints. Although anti-TNF therapies have proven effective in the management of RA, approximately one third of patients do not show a significant clinical response. The objective of this study was to identify new genetic variation associated with the clinical response to anti-TNF therapy in RA. We performed a sequential multi-omic analysis integrating different sources of molecular information. First, we extracted the RNA from synovial biopsies of 11 RA patients starting anti-TNF therapy to identify gene coexpression modules (GCMs) in the RA synovium. Second, we analyzed the transcriptomic association between each GCM and the clinical response to anti-TNF therapy. The clinical response was determined at week 14 using the EULAR criteria. Third, we analyzed the association between the GCMs and anti-TNF response at the genetic level. For this objective, we used genome-wide data from a cohort of 348 anti-TNF treated patients from Spain. The GCMs that were significantly associated with the anti-TNF response were then tested for validation in an independent cohort of 2,706 anti-TNF treated patients. Finally, the functional implication of the validated GCMs was evaluated via pathway and cell type epigenetic enrichment analyses. A total of 149 GCMs were identified in the RA synovium. From these, 13 GCMs were found to be significantly associated with anti-TNF response ( < 0.05). At the genetic level, we detected two of the 13 GCMs to be significantly associated with the response to adalimumab ( = 0.0015) and infliximab ( = 0.021) in the Spain cohort. Using the independent cohort of RA patients, we replicated the association of the GCM associated with the response to adalimumab ( = 0.0019). The validated module was found to be significantly enriched for genes involved in the nucleotide metabolism ( = 2.41e-5) and epigenetic marks from immune cells, including CD4+ regulatory T cells ( = 0.041). These findings show the existence of a drug-specific genetic basis for anti-TNF response, thereby supporting treatment stratification in the search for response biomarkers in RA.